Comparative Pharmacology
Head-to-head clinical analysis: ANCOBON versus MICONAZOLE 7.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANCOBON versus MICONAZOLE 7.
ANCOBON vs MICONAZOLE 7
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Flucytosine is converted intracellularly to 5-fluorouracil, which inhibits fungal RNA and DNA synthesis by incorporating into RNA and inhibiting thymidylate synthase.
Imidazole antifungal agent that inhibits fungal cytochrome P450 14α-demethylase, thereby blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
50-150 mg/kg/day orally divided every 6 hours; intravenous dosing: 50-150 mg/kg/day divided every 12 hours.
Apply 200 mg (one full applicator) intravaginally once daily at bedtime for 7 days.
None Documented
None Documented
Terminal elimination half-life 2.5-6 hours (normal renal function). Prolonged to 30-250 hours in renal impairment (CrCl < 20 mL/min). Half-life correlates with creatinine clearance.
Terminal half-life 24-30 hours; prolonged in hepatic impairment
Primarily renal excretion of unchanged drug (75-90% within 24 hours). Less than 1% eliminated as 5-fluorouracil metabolite. Biliary/fecal excretion negligible.
Primarily fecal (~50%) and renal (~<1% unchanged)
Category C
Category A/B
Antifungal
Antifungal